Filing Details

Accession Number:
0001209191-21-026474
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-13 18:04:21
Reporting Period:
2021-04-12
Accepted Time:
2021-04-13 18:04:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492426 Horizon Therapeutics Public Ltd Co HZNP Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1619500 Barry Moze C/O Horizon Therapeutics Plc
Connaught House, 1St Fl, 1 Burlington Rd
Dublin L2 4
Evp, Chief Admin. Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2021-04-12 51,253 $88.70 120,025 No 4 S Direct
Ordinary Shares Disposition 2021-04-12 8,195 $89.60 111,830 No 4 S Direct
Ordinary Shares Disposition 2021-04-12 6,165 $90.30 105,665 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.085 to $89.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.08 to $90.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.20 to $90.41 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.